A paper from Marcišauskas et al. reported that ALDOA in cyst fluids and serum can be used as a diagnostic biomarker to separate stage I type 1 and type 2 ovarian cancers from benign serous adenoma (Marcišauskas et al., 2019). The gene discussed is ALDOA; the disease is ovarian cancer.